Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. It does not tell you which form to take. That decision belongs to you and the clinician who writes your prescription.
Quick answer
Wegovy tablets and the Wegovy pen contain the same active ingredient: semaglutide. Both are prescription-only, both are started at a low dose and stepped up over months, and both carry the same boxed warning. What changes is how the medicine gets into you — and that changes your day. The pen is once weekly, any time of day, with or without meals, and lives in the fridge. The tablet is once daily, first thing in the morning, on an empty stomach, with no more than 4 ounces of plain water, followed by a 30-minute wait before food, other drinks, or other oral medicines.
If you are deciding between them, the honest framing is not "which one is better." It is "which routine can I actually keep, and what does my prescriber think fits my situation."
Use this routine in TakelyWhat is actually the same between the pill and the injection?
More than most comparison posts admit. Wegovy tablets and Wegovy injection share a single FDA prescribing information document — one label, two dosage forms.
Both are semaglutide, a GLP-1 receptor agonist. Both are indicated in combination with a reduced-calorie diet and increased physical activity, in adults, to reduce excess body weight and maintain that reduction long term, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. (The injection carries two further indications the tablet does not: use in adolescents aged 12 and older with obesity, and treatment of noncirrhotic MASH with moderate to advanced liver fibrosis.)
Both share the same boxed warning about the risk of thyroid C-cell tumors, and the same contraindications: a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or a prior serious hypersensitivity reaction to semaglutide.
Both start low and escalate slowly, specifically to reduce the risk of gastrointestinal side effects. And the label says plainly that using either one alongside another semaglutide product or another GLP-1 receptor agonist is not recommended.
So the pill is not a weaker cousin of the injection or a different class of drug. It is the same molecule taking a different road in.
What actually changes day to day?
This is the part that decides whether a routine survives contact with a real week.
| Wegovy tablets | Wegovy injection | |
|---|---|---|
| How often | Once daily | Once weekly, same day each week |
| Timing | Morning, on an empty stomach | Any time of day |
| Food and drink | Plain water only, up to 4 ounces; then wait at least 30 minutes before food, other beverages, or other oral medicines | With or without meals; no restriction |
| Form | Swallow whole — do not split, crush, chew, or dissolve | Subcutaneous injection into abdomen, thigh, or upper arm |
| Storage | Room temperature, 20–25 °C, kept in the original bottle to protect from moisture | Refrigerated, 2–8 °C; before the cap is removed it can be kept at 8–30 °C for up to 28 days |
| Travel | Bottle of 30 tablets, no cold chain | Cold chain to plan for, plus sharps disposal |
| A missed dose | Skip it and take the next dose the following day | Take it as soon as possible if the next scheduled dose is more than 2 days away; otherwise skip and resume on the usual day |
Notice which column has more rules. The pen's flexibility is real — the label explicitly says the time of day and the injection site can be changed without any dosage modification. The tablet buys you "no needles, no fridge" and charges you a fixed 30-minute window every single morning.
Neither trade is universally better. They are just different failure modes. A pen can be forgotten for a week; a pill can be swallowed with coffee.
Does the Wegovy pill work as well as the injection?
This is the most-searched version of the question, and it deserves a careful answer rather than a confident one.
There is no head-to-head trial of Wegovy tablets against Wegovy injection for weight reduction. The tablet's efficacy was established in one 64-week randomized, double-blind, placebo-controlled trial (Study 7 in the label, registered as NCT05564117, published as OASIS 4). The injection's efficacy was established in a separate set of 68-week trials. Those trials enrolled different people at different sites in different years. Comparing a number from one to a number from the other is a cross-trial comparison, not a head-to-head result, and it cannot tell you that one form outperformed the other.
What the label does say — and this is the closest thing to a direct comparison that exists — is about drug levels in the blood:
In patients without type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily or WEGOVY 2.4 mg injection once weekly were similar.
Two caveats sit right next to that sentence, and both matter.
First, variability. The tablet produces more spread between people than the pen does. In the label's pharmacokinetic modelling, 90% of patients on the 25 mg tablet had average concentrations between 27 and 186 nmol/L, versus 51 and 110 nmol/L on the 2.4 mg injection. Same average, wider scatter.
Second, type 2 diabetes. In patients with type 2 diabetes, average semaglutide concentrations on the 25 mg tablet were lower than on the 2.4 mg injection, which the label attributes to reduced absolute bioavailability. It goes on to say that some patients with type 2 diabetes taking the tablets may experience subtherapeutic concentrations, and that if the response is inadequate, switching to the injection is worth considering.
The honest version — "as well as" is a question for your prescriber.
The label supports the idea that the two forms can reach comparable drug levels in people without type 2 diabetes. It does not support a general claim that either form works better, and it flags a specific situation — type 2 diabetes — where the tablet may deliver less. Bring that paragraph to your appointment rather than settling it from a search result.
Do the side effects differ between the pill and the injection?
Mostly, no. The side effects people associate with "the pill" are GLP-1 side effects, not oral-formulation side effects.
The label reports that in the clinical trial with Wegovy tablets, the types and frequency of common adverse reactions were similar to those seen with the injection. For the injection, the reactions reported in at least 2% of treated adults and more often than placebo were led by nausea (44% vs 16% on placebo), diarrhea (30% vs 16%), vomiting (24% vs 6%), constipation (24% vs 11%), and abdominal pain (20% vs 10%), followed by headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, reflux, gastritis, and hair loss.
Discontinuation numbers are worth reading side by side, with the reminder that these come from different trials. In the injection trials, 6.8% of treated patients stopped because of an adverse reaction, versus 3.2% on placebo. In the tablet trial, 6.9% stopped versus 5.9% on placebo, and the most common reason was gastrointestinal reactions (3.4% vs 2%).
The same warnings and precautions apply to both forms: acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or an insulin secretagogue, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, diabetic retinopathy complications in type 2 diabetes, heart-rate increase, suicidal behaviour and ideation, and pulmonary aspiration during general anesthesia or deep sedation.
One practical difference is not on the side-effect list but shows up in daily life: because the tablet is daily, a rough stomach day is a decision you make every morning, while on the pen it is a decision you made on Sunday. That is a tolerability experience difference, not a safety difference.
Built for daily GLP-1 pills. Takely times the fasting window and logs how the morning actually went — so you have something concrete to bring to your next appointment. Open Takely →
What does each form cost?
Prices move, coverage varies, and nothing here is a quote. The figures below come from Novo Nordisk's own published US self-pay price guide and were checked on 31 July 2026. Check the current guide and your own plan before you plan around any number.
Self-pay, per month, through the manufacturer's pharmacy programme:
| Dose | Wegovy pill | Wegovy pen |
|---|---|---|
| Starting doses | 1.5 mg — $149; 4 mg — $149 (limited-time; $199 after 31 Aug 2026) | 0.25 mg and 0.5 mg — $199 for the first 2 fills for new patients through 31 Dec 2026, then $349 |
| Middle doses | 9 mg — $299 | 1 mg — $349; 1.7 mg — $349 |
| Maintenance | 25 mg — $299 | 2.4 mg — $349 |
For the pill, one month is defined as one bottle of 30 tablets; for the pen, one box of 4 pens. With commercial insurance that covers the medicine, the manufacturer's savings offer advertises "pay as little as $25" per month for all doses of either form, subject to a maximum saving of $100 per month, with government beneficiaries excluded and other eligibility conditions attached.
Two things to hold onto. The self-pay gap between the two forms is real but not dramatic — at maintenance dose it is roughly $50 a month at these published rates. And self-pay prices are not what most people pay; what your plan covers, and whether it covers weight management at all, will swamp the list price difference.
How do the dose schedules compare?
Both forms titrate. They just count in different units — the tablet in 30-day blocks, the pen in 4-week blocks. This table is here so you can recognise where you are in the process, not so you can adjust anything. Follow the schedule your prescriber gave you.
Wegovy tablets, once daily:
| Days | Dose |
|---|---|
| 1–30 | 1.5 mg |
| 31–60 | 4 mg |
| 61–90 | 9 mg |
| 91 onward | 25 mg (maintenance) |
Wegovy injection, once weekly:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1 mg |
| 13–16 | 1.7 mg |
| 17 onward | 2.4 mg (recommended maintenance) or 1.7 mg |
The label adds that if a dose is not tolerated during escalation, delaying the step up is an option — for the injection it suggests a 4-week delay. And if the 25 mg tablet maintenance dose is not tolerated, it raises switching to the 1.7 mg weekly injection as something to consider. Again: that is guidance written for prescribers, not a self-service menu.
What is the 30-minute window, and why does it exist?
Here is the difference nobody warns you about until day one.
Semaglutide is a peptide. Swallowed on its own, it would be largely destroyed before it was absorbed. The tablet solves this by co-formulating semaglutide with an absorption enhancer called SNAC, and absorption then happens predominantly in the stomach. Even so, absolute bioavailability of the tablet is estimated at roughly 1% to 2%, compared with 89% for the subcutaneous injection.
That thin margin is why the instructions are so specific. Anything in the stomach — food, coffee, juice, a large glass of water, another pill — competes with a process that barely works to begin with.
The label's own pharmacokinetic studies show it directly. Given with 50 mL of water versus 240 mL after an overnight fast, absorption was higher with the smaller volume. And in a 10-day study where healthy subjects fasted for 15, 30, 60, or 120 minutes after the dose, absorption was higher with a longer post-dose fast.
So the rule is not arbitrary caution. It is: empty stomach, in the morning, no more than 4 ounces of plain water, nothing else to drink, swallow whole, then wait at least 30 minutes before food, any beverage, or any other oral medicine.
If you take Rybelsus, this will look familiar — its label carries the same empty-stomach, up-to-4-ounces, wait-30-minutes instruction. We walk through the mechanics of that window in detail in the 30-minute wait, step by step, and compare the fasting rules across the oral GLP-1 brands in the oral GLP-1 comparison.
How do most people fit the window into a morning?
The 30 minutes is not the hard part. Remembering that it started is.
The pattern that tends to hold is to attach the tablet to something you already do at a fixed time — the alarm, the bathroom, feeding a pet — and then to fill the window with something that does not involve the kitchen. A shower. Getting dressed. A walk to the bus. The failure mode is almost always the same: taking the tablet, going back to a warm bed or a screen, and then losing track until the coffee is already poured.
The specific pressure points worth planning for are coffee (it is a beverage; it waits), other morning medicines (they wait too, and if any of them are time-critical, that is a conversation for your prescriber or pharmacist), and weekends, where the anchor you built around a workday alarm quietly disappears.
If you want a timer that knows the rule rather than a generic kitchen timer, that is what Takely's fasting window is for — it starts when you log the dose and tells you when food, coffee, and other oral medicines unlock.
Use the difference to ask a better question
If you are weighing the two forms, the useful appointment note is not "which is better." It is something like: "I travel two weeks a month and can't manage refrigeration," or "I already take three tablets first thing and can't stagger them," or "I've been on the pen for six months and want to know whether switching changes my dose."
That last one has an answer in the label, and it is worth knowing it exists: there are published instructions for switching in both directions. But the instruction is written for the person holding the prescription pad. Do not start, stop, switch, split, or combine anything based on a comparison table — including this one.
Frequently asked questions
Does the Wegovy pill work as well as the injection?
There is no head-to-head trial, so no direct answer exists. The label states that in people without type 2 diabetes, average semaglutide blood concentrations were similar on the 25 mg tablet once daily and the 2.4 mg injection once weekly — with more variability between people on the tablet. In people with type 2 diabetes, tablet concentrations were lower. Your prescriber is the right person to apply that to your situation.
Can I switch from the injection to the pill?
The label includes instructions for switching in both directions, including a specified gap when moving from the 2.4 mg injection to the 25 mg tablet. Those instructions are for your prescriber to apply. Do not change forms, doses, or timing on your own.
Do the side effects differ between the pill and the injection?
The label reports that the types and frequency of common adverse reactions in the tablet trial were similar to those with the injection. Gastrointestinal reactions — nausea, diarrhea, vomiting, constipation, abdominal pain — lead the list for both, and both escalate slowly to reduce that risk.
What happens if I eat too soon after taking the pill?
The label's studies show that a shorter post-dose fast, or a larger volume of water, produces lower absorption. It does not describe a single missed morning as dangerous, and it does not tell you to repeat the dose. Note what happened, do not take a second tablet, and mention a repeated pattern at your next appointment.
Do I have to take the pill in the morning?
The label instruction is to take it on an empty stomach in the morning with up to 4 ounces of water. It is not framed as a preference. If mornings genuinely do not work for you, that is a reason to talk to your prescriber, not a reason to improvise.
Does the Wegovy pill need to be refrigerated?
No. Tablets are stored at 20–25 °C and kept in the original bottle to protect them from moisture. The pen is stored in the refrigerator at 2–8 °C, and before the cap is removed it can be kept at 8–30 °C for up to 28 days.
What if I miss a dose?
The rules differ by form. For tablets: skip the missed dose and take the next one the following day. For the injection: if the next scheduled dose is more than 2 days away, take it as soon as possible; if it is less than 2 days away, skip it and resume on the usual day. If two or more consecutive injections are missed, the label raises re-escalation as something your prescriber may consider.
Primary sources and further reading
- FDA Prescribing Information — WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets, revised 12/2025 ↗
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets, revised 10/2025 ↗
- Novo Nordisk — FDA approval of the Wegovy pill (oral semaglutide 25 mg), December 2025 ↗
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) — N Engl J Med 2025;393:1077–1087, PMID 40934115 ↗
- NovoCare — Wegovy price guide, US26NC00049, April 2026 ↗
Prices and labels change. Cost figures on this page were verified on 31 July 2026 and are US self-pay prices published by the manufacturer, not a quote. Check the current label and ask your clinician or pharmacist about your own prescription.